Bayer, Sensyne to use AI platform to accelerate CV development

Bayer entered a two-year deal with AI platform company Sensyne to mine NHS data with the goal of accelerating clinical development of new treatments for cardiovascular disease, including heart failure and stroke.

Sensyne CEO Paul Drayson told BioCentury that the company is analyzing anonymized NHS patient data "to be able to better stratify patients at risk of heart disease and stroke, [and] to be able to improve clinical trial design for future cardiovascular clinical trials." NHS has identified CV disease as a clinical priority. ...